Pharmaceutical manufacturing faces a new US tariff challenge of 100%
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
The US generic pharmaceutical industry is facing another period of uncertainty after President Donald Trump announced plans to impose a 100% tariff on imported generic medicines beginning in August 2028. Companies that continue manufacturing overseas would face a 200% tariff a year later unless they establish production capacity in the US. The proposal extends the administration’s effort to encourage domestic manufacturing while increasing pressure on one of healthcare’s most cost-sensitive industries.
Generic medicines account for more than 90% of prescriptions dispensed in the US, making them central to affordable healthcare. Unlike branded pharmaceuticals protected by patents, generic manufacturers compete primarily on price. That leaves little room to absorb higher production costs without affecting profitability or supply.
Although the proposed tariffs remain two years away, they have already altered the strategic outlook for manufacturers, suppliers and investors. Pharmaceutical companies must decide whether to invest in new US facilities, restructure global production networks or wait for further policy developments before committing capital.
The economics of generic medicines leave little room for higher costs
Trump’s proposal focuses specifically on generic medicines while maintaining a separate approach for patented drugs. The administration argues the tariffs will encourage manufacturers to relocate production to the US instead of relying on overseas facilities.
For generic manufacturers, the economics are far less straightforward.
The sector operates on exceptionally thin margins. Companies compete aggressively for contracts from wholesalers, pharmacy chains and hospital systems, leaving limited flexibility to absorb additional costs. Establishing new manufacturing facilities in the US requires significant investment, regulatory approval and several years before production can begin.
The proposed timeline reflects those practical realities. Tariffs would begin in August 2028 before increasing to 200% in 2029, creating a narrow window for manufacturers to evaluate investment plans.
Financial markets reacted quickly following the announcement. Shares of several European and Indian generic drug manufacturers declined as investors assessed the potential effect on earnings and future production strategies.
Global supply chains have taken decades to build
The proposal also highlights the complexity of pharmaceutical manufacturing.
Many generic medicines supplied to US patients are produced in India, China and Europe through supply chains that have developed over several decades. Those facilities often manufacture medicines for multiple international markets, allowing companies to spread production costs across higher volumes.
Relocating production involves far more than constructing new factories. Manufacturers must recruit skilled employees, validate production processes, qualify suppliers, secure regulatory approvals and establish distribution networks. Each stage can require months or years, particularly for medicines produced under tightly controlled manufacturing standards.
Industry groups have argued that tariffs alone may not be enough to encourage widespread reshoring without broader incentives that improve the economics of domestic production. Policymakers, meanwhile, continue to emphasize supply chain resilience following disruptions experienced during the pandemic and subsequent geopolitical tensions.
Healthcare providers are also watching developments closely. Generic medicines span almost every therapeutic category, including antibiotics, cardiovascular treatments, oncology drugs and diabetes therapies. Any disruption to established supply chains could affect both product availability and pricing if manufacturers struggle to relocate production.
Manufacturers now face long-term strategic choices
Although implementation remains several years away, the announcement effectively begins a new planning cycle for the pharmaceutical industry.
Companies with existing US manufacturing operations may be better positioned to expand domestic capacity. Those that rely heavily on overseas production face more difficult investment decisions. Some manufacturers may accelerate planned US projects, while others are likely to wait for greater policy certainty before committing substantial capital.
The proposal also reflects a broader shift in US industrial policy. Recent trade measures have increasingly linked access to the American market with domestic manufacturing across industries including semiconductors, electric vehicles and pharmaceuticals. Generic medicines have now become part of that wider strategy.
Whether the proposal ultimately reshapes pharmaceutical manufacturing will depend on how companies respond over the next two years and whether additional incentives accompany the tariff plan. What is already evident is that supply chain strategy has become a boardroom priority. Investment decisions made before 2028 are likely to shape where generic medicines are produced, how resilient supply networks become and what patients ultimately pay for some of the world’s most widely prescribed treatments.
Source:
Bloomberg